Dr. Wierda Discusses the Role of Ibrutinib in CLL

William G. Wierda, MD, PhD
Published: Wednesday, Oct 11, 2017



William G. Wierda, MD, PhD, medical director of the Leukemia Center at The University of Texas MD Anderson Cancer Center, discusses the role of ibrutinib (Imbruvica) in the treatment of patients with chronic lymphocytic leukemia (CLL).

Considering all the progress being made with novel therapies in this disease, ibrutinib remains a vital part of frontline treatment for patients with CLL, says Wierda.

Currently, trials investigating dosing are aiming to determine whether a lower dose of ibrutinib may be as effective or better tolerated than 420 mg.
 


William G. Wierda, MD, PhD, medical director of the Leukemia Center at The University of Texas MD Anderson Cancer Center, discusses the role of ibrutinib (Imbruvica) in the treatment of patients with chronic lymphocytic leukemia (CLL).

Considering all the progress being made with novel therapies in this disease, ibrutinib remains a vital part of frontline treatment for patients with CLL, says Wierda.

Currently, trials investigating dosing are aiming to determine whether a lower dose of ibrutinib may be as effective or better tolerated than 420 mg.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: Management of Adverse Events Associated with Therapies for Hematological Disorders: Nurses' PerspectiveApr 21, 20182.0
Community Practice Connections™: Oncology Best Practice™: Choosing Therapies for Patients with EGFR-mutant Lung Cancers: More Options... More Decisions... Better OutcomesApr 27, 20182.0
Publication Bottom Border
Border Publication
x